---
title: "AIM: Earnings rebounded on Bozzetto sale, with strong cash growth and ongoing cost discipline"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295519206.md"
description: "Net earnings surged to $33.3 million from a $6.1 million loss year-over-year, driven by the $270 million Bozzetto sale and favorable FX. Revenue and Adjusted EBITDA declined, while cash reserves rose sharply. Focus remains on capital allocation, cost control, and Cortland turnaround.Original document: Aimia Inc. [AIM] Earnings Release — Aug. 11 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-11T10:13:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295519206.md)
  - [en](https://longbridge.com/en/news/295519206.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295519206.md)
generator: "portal-rs"
---

# AIM: Earnings rebounded on Bozzetto sale, with strong cash growth and ongoing cost discipline

Net earnings surged to $33.3 million from a $6.1 million loss year-over-year, driven by the $270 million Bozzetto sale and favorable FX. Revenue and Adjusted EBITDA declined, while cash reserves rose sharply. Focus remains on capital allocation, cost control, and Cortland turnaround.

Original document: Aimia Inc. \[AIM\] Earnings Release — Aug. 11 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [AIM.US](https://longbridge.com/en/quote/AIM.US.md)

## Related News & Research

- [AIM ImmunoTech Converts ~$450,000 of Note Into 1.92M Shares in Exchanges With Streeterville](https://longbridge.com/en/news/298643679.md)
- [AIM ImmunoTech issues 1,921,441 shares in $450,000 debt exchange with Streeterville Capital](https://longbridge.com/en/news/298642254.md)
- [The AI doom debate is getting carried away. AI is a product, not a god.](https://longbridge.com/en/news/298967924.md)
- [Inside the generational clash over AI in math: 'We don’t have the luxury of waiting'](https://longbridge.com/en/news/298886174.md)
- [NPCE: FDA approval for IGE and AI-driven tools could significantly expand market reach and accelerate growth](https://longbridge.com/en/news/298482113.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**